NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN
THE UNITED STATES


VentriPoint Diagnostics Ltd. ("VentriPoint" or the "Corporation") (TSX
VENTURE:VPT) is pleased to announce that is has completed a closing of its
previously announced private placement of units with Bloom Burton & Co. Inc.
(the "Agent") as the agent on a best efforts basis. The private placement also
included a non-brokered component. The Corporation issued a total of 8,680,385
units at a price of $0.17 per unit for total gross proceeds of $1,475,666. Each
unit consists of one common share and one half of one common share purchase
warrant. Each whole warrant entitles the holder thereof to acquire one
additional common share at a price of Cdn.$0.25 per share for a period of 36
months after the closing. All securities issued in connection with the offering
will be subject to a four month hold period that expires on April 24, 2011.
Completion of the private placement is subject to TSX Venture Exchange final
approval. The net proceeds of the private placement will be used for: (i)
expenditures with respect to product and service commercialization of the
VentriPoint Medical System ("VMS"); (ii) expansion of VMS functionality,
including applications for additional diagnoses and heart diseases; and (iii)
for working capital. VentriPoint and Bloom Burton have received additional
subscription agreements that are expected to be closed on shortly as a second
tranche of the private placement.


For its services in connection with the Offering, the Agent was paid fees in the
aggregate amount of $104,210 and received an aggregate of 613,001 broker
warrants. Each broker warrant entitles the holder thereof to purchase one common
share at an exercise price of Cdn.$0.17 for a period of 36 months after the
closing.


George Adams, the President and CEO of the Corporation, subscribed for 300,000
units under the offering. VentriPoint has determined that there are exemptions
available from the various requirements of TSX Venture Policy 5.9 and
Multilateral Instrument 61-101 for the issuance of these units, (Formal
Valuation - Issuer Not Listed on Specified Markets; Minority Approval - Fair
Market Value Not More Than 25% of Market Capitalization). No new insiders were
created, nor has any change of control occurred, as a result of this private
placement.


About VentriPoint Diagnostics Ltd. - VentriPoint has created a diagnostic
ultrasound tool to monitor patients with heart disease, a leading cause of death
in developed countries. VMS is the first cost-effective and accurate diagnostic
tool for measuring right ventricle heart function. Congenital heart disease in
children is the first application in a suite of applications for all major heart
diseases including pulmonary hypertension, cardiovascular disease and heart
failure - a multibillion dollar market potential. Canada and Europe (CE Mark)
have granted approval for the sale of its VMS diagnostic tool and a 510(k)
submission is currently being reviewed by the U.S. Federal Drug Administration.


Cautionary Note Regarding Forward-Looking Statements - Certain statements
contained herein constitute forward-looking statements, including statements
concerning the anticipated closing date of the Offering and the anticipated use
of proceeds. We believe the expectations reflected in those forward-looking
statements are reasonable but no assurance can be given that these expectations
will prove to be correct and such forward-looking statements included herein
should not be unduly relied upon. Closing could be delayed if VentriPoint cannot
obtain necessary regulatory approvals within anticipated timelines and will not
be completed unless certain conditions customary for transactions of this kind
are satisfied. The forward-looking statements included in this press release are
made as of the date of this press release and VentriPoint disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, except as
expressly required by applicable securities legislation.


This news release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there by any sale of the securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful.
Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Vortex Metals Charts.
Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Vortex Metals Charts.